Hurdles toward a cure for CML: the CML stem cell.

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• Chronic myeloid leukemia (CML) serves as a paradigm for understanding oncogene addiction and targeted cancer therapies.
• Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, significantly improving patient outcomes in the chronic phase (CP).
• However, CML cancer stem cells (CSCs) are resistant to TKIs, representing a major obstacle to achieving a definitive cure.

Purpose of the Study:

• To review the critical role of cancer stem cells (CSCs) in chronic phase CML (CP-CML).
• To discuss the persistence of CML CSCs despite tyrosine kinase inhibitor (TKI) therapy.
• To examine current and emerging strategies aimed at eradicating CML CSCs for a potential cure.

Main Methods:

• Literature review of studies on CML pathogenesis, CSC biology, and TKI resistance.
• Analysis of research on therapeutic approaches targeting cancer stem cells in CML.
• Synthesis of current understanding regarding CSC persistence and treatment strategies.

Main Results:

• CSCs are implicated in CML pathogenesis and are refractory to standard TKI treatment.
• The persistence of CML CSCs following TKI therapy is a key factor in disease relapse and treatment failure.
• Targeting CSCs presents a promising avenue for achieving durable responses and potentially curing CML.

Conclusions:

• Cancer stem cells (CSCs) are a significant barrier to curing chronic myeloid leukemia (CML).
• Developing effective strategies to eliminate CML CSCs is crucial for achieving long-term disease remission.
• Future research should focus on novel therapeutic approaches that specifically target the CML CSC population.